<DOC>
	<DOCNO>NCT01383096</DOCNO>
	<brief_summary>This study design assess prototype formulation compare aqueous dispersion Active Pharmaceutical Ingredient use Phase I Phase IIa study date . It hop bioavailability OZ439 enhance fast state close observe give food . This improve utility OZ439 field well decrease cost treatment ( decrease dose OZ439 require ) important antimalarial drug product destine use develop county .</brief_summary>
	<brief_title>Study To Investigate The Relative Bioavailability OZ439 Formulations In Healthy Volunteers</brief_title>
	<detailed_description>This study single centre , open-label , pharmacokinetic , randomize cross-over study healthy male volunteer post-menopausal woman . This study conduct three different cohort follow : Cohort 1 : Subjects receive single 800 mg ( free base ) dose five different treatment regime ( treatment A , B , C , D E ) five occasion . Cohort 2 : Subjects receive single 800 mg ( free base ) dose four different treatment regime ( treatment F , G , H I ) four occasion . Cohort 3 : Subjects receive single dose , 800mg ( free base ) prototype solution formulation 1 ( treatment J ) 400mg ( free base ) prototype solution formulation 1 ( treatment K ) two occasion . The treatment administer fasted state .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male female volunteer 18 55 year ( inclusive ) . Postmenopausal woman amenorrhoea least 2 year eligible confirm FSH level &gt; / = 25microlU/ml Body mass Index 18 30 kg/m2 , inclusive ; body weight &gt; 50 kg . Healthy determine prestudy medical history , physical examination ( include body temperature ) , 12 Lead ECG . Male volunteer must agree use double barrier method contraception include abstinence , condom plus diaphragm condom plus IUD condom plus stable oral/transdermal/injectable hormonal contraceptive female partner least 14 day prior time first dose study drug 90 day last dose study drug must also agree donate sperm 90 day last dose study drug . Vasectomy zero sperm count 6 month minimum prior first dose study drug acceptable form contraception Clinical laboratory test screen within reference range outside normal range clinically significant . ALT , AST total bilirubin must within normal range Able willing give write informed consent Willing able adhere lifestyle guideline requirement Willing able confined Clinical Research Unit require protocol Evidence history clinically significant oncologic , pulmonary , hepatic , cardiovascular , hematologic , metabolic , neurological , immunologic , nephrologic , endocrine , psychiatric disease , current infection Evidence history clinically significant gastrointestinal ( exclude appendectomy cholecystectomy ) disease current infection . Any condition could possibly affect drug absorption , e.g . gastrectomy , diarrhea History postantibiotic colitis Pregnancy breastfeed QTc great 450 msec male female correct Fredricia 's formula evidence history abnormal cardiac rhythm History drug alcohol abuse within past 2 year prior Screening Tobacco user ( include stop smoke less 90 day prior screen . `` Tobacco use '' include smoking use snuff chew tobacco , nicotine containing product Received investigational drug participate another research study within 30 day first dose study drug part study Use prescription drug within 14 day prior first dose study drug Period 1 , need antibiotic study Received non prescription medication , vitamin , herbal supplement dietary supplement within 7 day first dose study drug Period 1 , unless prior approval grant . Excluded list intermittent use acetaminophen dose 2 g/day Consumed alcohol within 72 hour Day 1 part study , positive alcohol screen screen admission Consumed fruit juice ate grapefruit within 7 day prior first dose study drug part study Positive test human immunodeficiency virus , hepatitis B surface antigen antihepatitis C virus Positive urine drug screen Screening admission History intolerance hypersensitivity artemisinins Likelihood require treatment study period drug permit study protocol Volunteers donate blood experienced significant blood loss within 90 day screen Hemoglobin &lt; 13.5 g/dL male &lt; 12.5 g/dL female Any concern investigator regard safe participation volunteer reason investigator considers volunteer inappropriate participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>OZ439</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Food Effect</keyword>
</DOC>